Case Study: Fortune 100 Pharmaceutical Company achieves post-merger clinical data convergence, $200M multiyear contract and major cost savings with GEP

How GEP Helped a Global Pharma Giant Drive Synergies Through Post-Merger Clinical Data Ecosystem Integration

A Fortune 100 pharmaceutical company faced the complex task of converging clinical trial data ecosystems after a record-breaking M&A. COVID-driven uncertainty, tight timelines and fragmented licensing and software landscapes made it hard to define future requirements, rationalize processes across two legacy organizations and renegotiate supplier arrangements without risking trial delays and revenue impact.

GEP conducted a deep dive into 100+ agreements, analyzed clinical and supplier data, ran stakeholder workshops and scenario models, and led multiple rounds of fact-based negotiations. The work delivered ~7% savings on annual licensing, ~30% savings on managed services, a ~$200M multiyear contract with clearer, fixed pricing and improved T&Cs, and a redesigned governance model for faster decisions and stronger supplier management.